Trust depends on knowing what is established, built, demonstrated, and still planned.
MbeleMed separates published evidence, internal models, platform capabilities, synthetic demonstrations, pilot-stage work, and roadmap items so buyers can evaluate the company without conflating maturity levels.
Every claim should carry its maturity on its face.
Published evidence
Externally published clinical or operational evidence, cited with source, population, and limitations.
Modeled economics
Internal financial or outcomes modeling with assumptions, sensitivities, and exclusions stated explicitly.
Platform capability
A capability implemented in the platform or operating design, without implying production scale or clinical validation.
Demonstrated workflow
A workflow shown with synthetic data for review, training, or partner discussion. It is not a live deployment.
Pilot-stage
Scoped work governed by an agreed population, protocol, endpoints, and approval pathway.
Roadmap
A planned capability or application that has not yet reached the maturity described by the other categories.
Clinical authority remains with qualified clinicians.
MbeleMed is designed to coordinate population selection, monitoring access, physician review, outreach, escalation, and evidence capture. It does not autonomously diagnose, prescribe, treat, or replace clinical judgment.
- No autonomous diagnosis or treatment.
- Potential findings are routed through qualified physician review before clinical action.
- Escalation and follow-up rules are defined with the partner and applicable clinicians.
- Monitoring devices and professional interpretation remain attributable to the applicable third parties.
- Operational records are designed to support review and accountability.
Public demonstrations use synthetic data.
It does not contain protected health information, perform autonomous clinical decision-making, or represent a live production deployment.
A synthetic demonstration can show interface behavior, workflow logic, safety controls, audit concepts, and intended handoffs. It cannot establish clinical performance, real-world outcomes, production readiness, customer adoption, reimbursement, or compliance certification.
Commercial and clinical claims require traceability.
External statements should identify their source, assumptions, maturity, approval status, and relevant limitations. MbeleMed does not use universal ROI, savings, reimbursement, outcome, certification, or category-leadership claims without appropriate support.
Commercial structures
MbeleMed can support partner-specific arrangements, including structures in which MbeleMed’s fee is tied to physician-confirmed actionable detections. Device costs, professional interpretation, downstream care, billing eligibility, and realized economics depend on the applicable partner, patient, contract, and clinical pathway.
Security, privacy, billing, and regulatory statements
These statements should be limited to controls actually implemented and readiness levels actually achieved. Roadmap commitments must not be presented as current certifications or completed capabilities.
Maternal cardiac instability remains research and pilot-stage.
MbeleMed is exploring a prenatal and postpartum pathway focused on cardiac instability detection and escalation. This is not presented as a commercially available program, validated clinical product, or equivalent in maturity to the senior and value-based-care wedge.
Define the evidence before the pilot begins.
A credible pilot should specify the population, monitoring pathway, clinical authority, operational controls, endpoints, and economic assumptions before launch.